R&D cutbacks loom at Millennium's Cambridge ops

The new president at Millennium Pharmaceuticals has been trying to maintain a careful balancing act in recent weeks, trying to reassure staffers about Takeda's commitment to the oncology subsidiary while making it clear that cuts are coming. In an interview with the Boston Globe's Robert Weisman, Millenium President Anna Protopapas reiterated earlier remarks about a reorganization in the wake of Deborah Dunsire's high-profile departure. "Takeda is trying to eliminate some duplication," she tells Weisman. "There is no change in the commitment to oncology research. Takeda recognizes that this area is a center of innovation in life sciences, and it is committed to having a significant presence here." To help underscore the upside, Protopapas also said that Takeda is looking at setting up a translational research lab at Millennium, which sits in the center of one of the world's largest biotech hubs. But that suggestion may not ease many worried minds in research. Story

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.